Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Says negotiations have commenced with GlobalCo regarding the form of licensing and further development of leukaemia product candidate CDX toward clinical trials. The results of negotiations and outline of path toward the further development of CDX will be announced upon their completion, it adds.
"We are pleased with the continued interest of GlobalCo in facilitating the advancement of the CDX antibody toward the clinic, having concluded the highly successful development phase of this product candidate. We are also excited about the progress being made in moving HEMO-CAR-T toward clinical trials. Having two lead product candidates that have resulted in collaborations with such esteemed organizations and both moving toward clinical trials is testament to the company's exceptional team of scientists and our dedication to cutting edge science," says CEO Vladislav Sandler.
Current stock price: 6.80 pence
Year-to-date change: down 28%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Hemogenyx (HEMO)